<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39321181</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>9</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>A SONAR report on Nirmatrelvir/ritonavir-associated rebound COVID-19: Using new databases for evaluating new diseases.</ArticleTitle><Pagination><StartPage>e0308205</StartPage><MedlinePgn>e0308205</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0308205</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0308205</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">In May 2022, the Centers for Disease Control and Prevention disseminated an alert advising that "a few" persons with Nirmatrelvir/ritonavir (NM/R)-associated rebound of COVID-19 infection had been identified. Three case reports appearing as pre-print postings described the first cases. Analyses in March 2023 by NM/R's manufacturer and the Food and Drug Administration (FDA) reported no association between NM/R and COVID-19 rebound in a large phase 3 randomized clinical trial. Our study evaluated if social media databases or electronically disseminated new articles might provide insights related to the putative new toxicity, NM/R-associated COVID-19 rebound.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Information on NM/R-associated COVID-19 rebound cases was abstracted from preprint postings of non-peer-reviewed manuscripts, social media websites, electronically disseminated print and television media reports, a new FDA adverse event database for drugs that received Emergency Use Approval, and news articles in scientific journals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-five persons experienced presumed or documented NM/R-associated COVID-19 rebound, based on information described in preprint services (n = 27), Twitter postings and related news articles (n = 7), and news articles without related Twitter reports (n = 1). These reports included information on dates of initial COVID-19 illness and rebound onset, COVID-19 testing, vaccine status, presentation, and outcome. A new FDA safety database identified 12,500 possible cases of this toxicity, but the quality of these data was poor. Preprint postings preceded peer-reviewed publications describing the same cases by four months. Social media websites including Instagram, Reddit, YouTube, the Center for Disease Control and Prevention's (CDC) Health Alert Network, CDC Twitter, and Facebook did not provide clinically meaningful information on individual cases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Preprint services and Twitter facilitated identification of the largest case series of NM/R-associated COVID-19 rebound. The cases were reported in non-peer-reviewed media several weeks prior to the first peer-reviewed electronically disseminated publication of one person with this diagnosis.</AbstractText><CopyrightInformation>Copyright: Â© 2024 Bennett et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0002-8645-5705</Identifier><AffiliationInfo><Affiliation>Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magagnoli</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gundabolu</LastName><ForeName>Krishna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Department of Internal Medicine, Omaha School of Medicine University of Nebraska, Omaha, Nebraska, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Georgantopoulos</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4113-6655</Identifier><AffiliationInfo><Affiliation>Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lebby</LastName><ForeName>Akida</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Gretchen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopf</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology/Oncology, Highland Hospital, Alameda Health System, Oakland, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Kenneth R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine Northwestern University, Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrushesky</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nabhan</LastName><ForeName>Chadi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zyszkowski</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gale</LastName><ForeName>Robert Peter</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>City of Hope Comprehensive Cancer Center and the Beckman Research Institute, Duarte, California, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007191">Indazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="Y">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061108" MajorTopicYN="Y">Social Media</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007191" MajorTopicYN="N">Indazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>22</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39321181</ArticleId><ArticleId IdType="pmc">PMC11423969</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0308205</ArticleId><ArticleId IdType="pii">PONE-D-23-36065</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lu ZK, Kessler SJ, Schulz R, Bian J, Chen B, Wu J. Systematic approach to pharmacovigilance beyond the limits: the southern network on adverse reactions (SONAR) projects. Adv Pharmacoepidemiol Drug Saf. 2014;3(2).</Citation></Reference><Reference><Citation>Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination. The New England journal of medicine. 2021;384(20):1964â5. doi: 10.1056/NEJMc2105869</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2105869</ArticleId><ArticleId IdType="pmc">PMC8063883</ArticleId><ArticleId IdType="pubmed">33852795</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai EY, Lee KA, Nathanson AB, Leonelli AT, Petros BA, Brock-Fisher T, et al.. Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir. medRxiv. 2022:2022.08.04.22278378. doi: 10.1101/2022.08.04.22278378</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.04.22278378</ArticleId><ArticleId IdType="pmc">PMC9387148</ArticleId><ArticleId IdType="pubmed">35982651</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay AP, Jennifer MR, Danielle C, Emily S, Jeff P, Mira D, et al.. The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences Between Paxlovid and Untreated COVID-19 Participants. medRxiv. 2022:2022.11.14.22282195.</Citation></Reference><Reference><Citation>Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. medRxiv. 2022. doi: 10.1101/2022.06.21.22276724</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.21.22276724</ArticleId><ArticleId IdType="pmc">PMC9258292</ArticleId><ArticleId IdType="pubmed">35794889</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC Health Advisory. COVID-19 rebound after Paxlovid treatment. In: CDC Health Alert Network. emergency.cdc.gov: CDC; 2022 p. 4. https://emergency.cdc.gov/han/2022/pdf/CDC_HAN_467.pdf (accessed 9/1/2024).</Citation></Reference><Reference><Citation>Carlin AF, Clark AE, Chaillon A, Garretson AF, Bray W, Porrachi M, et al.. Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment. Res Sq. 2022. doi: 10.21203/rs.3.rs-1662783/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1662783/v1</ArticleId><ArticleId IdType="pmc">PMC9128786</ArticleId><ArticleId IdType="pubmed">35611335</ArticleId></ArticleIdList></Reference><Reference><Citation>Charness ME, Gupta K, Stack G, Strymish J, Adams E, Lindy DC, et al.. Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment. The New England Journal of Medicine. 2022;387(11):1045â7. doi: 10.1056/NEJMc2206449</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206449</ArticleId><ArticleId IdType="pmc">PMC9511633</ArticleId><ArticleId IdType="pubmed">36069968</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. FDA launches COVID-19 EUA FAERS public dashboard. Twitter.com; 2021.</Citation></Reference><Reference><Citation>Pandit JA, Radin JM, Chiang DC, Spencer EG, Pawelek JB, Diwan M, et al.. The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls. Clin Infect Dis. 2023;77(1):25â31. doi: 10.1093/cid/ciad102</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad102</ArticleId><ArticleId IdType="pmc">PMC10320179</ArticleId><ArticleId IdType="pubmed">36810665</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Adverse Event Reporting System (FAERS) Public Dashboard [Internet]. FDA. 2021 [cited 04/09/23]. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard.</Citation></Reference><Reference><Citation>Alshanqeeti S, Bhargava A. COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature. Cureus. 2022;14(6):e26239. doi: 10.7759/cureus.26239</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.26239</ArticleId><ArticleId IdType="pmc">PMC9308388</ArticleId><ArticleId IdType="pubmed">35898366</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli G, Focosi D, Turriziani O, Tuccori M, Brandi R, Fillo S, et al.. Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation. Clin Microbiol Infect. 2022;28(12):1657â8. doi: 10.1016/j.cmi.2022.06.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.06.029</ArticleId><ArticleId IdType="pmc">PMC9250152</ArticleId><ArticleId IdType="pubmed">35792281</ArticleId></ArticleIdList></Reference><Reference><Citation>Axios. Executive in the Biden Administration tests positive for âreboundâ COVID. www.Twitter.com: Twitter; 2022.</Citation></Reference><Reference><Citation>Boucau J, Uddin R, Marino C, Regan J, Flynn JP, Choudhary MC, et al.. Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases. 2023;76(3):e526âe9. doi: 10.1093/cid/ciac512</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac512</ArticleId><ArticleId IdType="pmc">PMC9384370</ArticleId><ArticleId IdType="pubmed">35737946</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenda Goodman VL. Fauci says his Covid rebounded after Paxlovid CNN 2022 06/30/22 (col. 2022).</Citation></Reference><Reference><Citation>Smith-Schoenwalder C. Biden tests positive for 7th straight day after âReboundâ COVID-19 infection. US News. 2022 08/05/22.</Citation></Reference><Reference><Citation>FDA. FDA briefing document for nirmatrelvir (NDA# 217188). March 16, 2023. https://www.fda.gov/media/166197/download (accessed 9/1/2024)</Citation></Reference><Reference><Citation>Coulson JM, Adams A, Gray LA, Evans A. COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy. J Infect. 2022;85(4):436â80. doi: 10.1016/j.jinf.2022.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.06.011</ArticleId><ArticleId IdType="pmc">PMC9212499</ArticleId><ArticleId IdType="pubmed">35718206</ArticleId></ArticleIdList></Reference><Reference><Citation>Epling BP, Rocco JM, Boswell KL, Laidlaw E, Galindo F, Kellogg A, et al.. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment. Clinical Infectious Diseases. 2023;76(4):573â81. doi: 10.1093/cid/ciac663</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac663</ArticleId><ArticleId IdType="pmc">PMC9619622</ArticleId><ArticleId IdType="pubmed">36200701</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley KE. LD. Biden experiences a COVID rebound after treatment with one course of Paxlovid. Politico. 2022 07/30/22.</Citation></Reference><Reference><Citation>The White House. An update from Dr. Kevin OâConnor, Physician to the President. www.Twitter.com: Twitter; 2022.</Citation></Reference><Reference><Citation>The Associated Press. First lady Jill Biden has âreboundâ COVID-19 case, President Joe Biden still testing negative PBS News. 2022 08/24/22.</Citation></Reference><Reference><Citation>Rubin R. From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid. JAMA. 2022;327(24):2380â2. doi: 10.1001/jama.2022.9925</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.9925</ArticleId><ArticleId IdType="pubmed">35675094</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares H. BM, Cardin R, Leister-Tebbe H., Zhu Y., Guan S., et al. Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or Mutations. 2022.</Citation></Reference><Reference><Citation>Hotez P. Twitter Thread. www.Twitter.com: Twitter; 2022.</Citation></Reference><Reference><Citation>Judd D, Cole D. Biden still testing positive after rebound COVID-19 case but âcontinues to feel well,â White House says. CNN. August 1, 2022. https://www.cnn.com/2022/07/31/politics/joe-biden-covid-positive-day-two/index.html (accessed 9/1/2024).</Citation></Reference><Reference><Citation>Scribner H. Biden negative for COVID after weeklong âreboundâ case. Axios. 8/6/2022. https://www.axios.com/2022/08/06/joe-biden-covid-19-case-negative (accessed 9/1/2024)</Citation></Reference><Reference><Citation>McPhillips E. COVID-19 rebound is probably more common than data suggests, but Paxlovid is still effective. CNN. 2022 08/26/22. https://www.cnn.com/2022/08/26/health/paxlovid-rebound-how-common/index.html (accessed 9/1/2024).</Citation></Reference><Reference><Citation>Washington Desk. First lady Jill Biden tests positive for COVID-19 in rebound case. NPR. 2022 08/24/22. https://www.npr.org/2022/08/24/1119262837/first-lady-jill-biden-tests-positive-covid-19-paxlovid-rebound (accessed 9/1/2024)</Citation></Reference><Reference><Citation>The Associated Press Staff. US First Lady Jill Biden tests negative for COVID after rebound. CTV News. 08/29/22. https://www.ctvnews.ca/mobile/health/coronavirus/u-s-first-lady-jill-biden-tests-negative-for-covid-after-rebound-1.6047745?cache=yesclipId10406200text/html;charset=utf-80404/7.314145/7.314145 (accessed 9/1/2024).</Citation></Reference><Reference><Citation>Daily Covid Briefing. Fauci says he believes Paxlovid kept him out of the hospital, even though he tested positive again. The New York Times 2022 06/29/22. https://www.nytimes.com/live/2022/06/29/world/covid-19-mandates-vaccine-cases (accessed 9/1/2024).</Citation></Reference><Reference><Citation>Kaplan K. Coronavirus today: Is the Paxlovid rebound real. The LA Times. 2022 11/15/22. https://www.latimes.com/science/newsletter/2022-11-15/coronavirus-today-paxlovid-rebound-coronavirus-today (accessed 9/1/2024).</Citation></Reference><Reference><Citation>Sheehan M. CDC boss tests positive for Covid AGAIN: Rochelle Walensky is diagnosed with virus just days after being given the all-clear. The Daily Mail. 2022 10/31/22. https://www.dailymail.co.uk/health/article-11374893/CDC-boss-tests-positive-Covid-Rochelle-Walensky-suffers-Paxlovid-rebound.html (accessed 9/1/2024).</Citation></Reference><Reference><Citation>Saad N. Stephen Colbert gets COVID-19 again, cancels âLate Show.â The LA Times. 2022 05/09/22. https://www.latimes.com/entertainment-arts/tv/story/2022-05-09/stephen-colbert-covid-19-recurrence-cancels-late-show-episodes (accessed 9/1/2024).</Citation></Reference><Reference><Citation>The Associated Press. CDC Director Rochelle Walensky tests positive for COVID again after taking a course of the anti-viral Paxlovid. NBC News. 2022 10/31/22. https://www.nbcnews.com/news/us-news/cdc-director-tests-positive-covid-paxlovid-rebound-case-rcna54870 accessed 9/1/2024).</Citation></Reference><Reference><Citation>Li M, Zhang QS, Liu XL, Wang HL, Liu W. Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS. Pharmaceuticals (Basel). 2022;15(12). doi: 10.3390/ph15121455</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15121455</ArticleId><ArticleId IdType="pmc">PMC9786063</ArticleId><ArticleId IdType="pubmed">36558906</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser N, Brierley L, Dey G, Polka JK, Palfy M, Nanni F, et al.. The evolving role of preprints in the dissemination of COVID-19 research and their impact on the science communication landscape. PLoS Biol. 2021;19(4):e3000959. doi: 10.1371/journal.pbio.3000959</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3000959</ArticleId><ArticleId IdType="pmc">PMC8046348</ArticleId><ArticleId IdType="pubmed">33798194</ArticleId></ArticleIdList></Reference><Reference><Citation>Chretien KC, Azar J, Kind T. Physicians on Twitter. JAMA. 2011;305(6):566â8. doi: 10.1001/jama.2011.68</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2011.68</ArticleId><ArticleId IdType="pubmed">21304081</ArticleId></ArticleIdList></Reference><Reference><Citation>Choo EK, Ranney ML, Chan TM, Trueger NS, Walsh AE, Tegtmeyer K, et al.. Twitter as a tool for communication and knowledge exchange in academic medicine: A guide for skeptics and novices. Med Teach. 2015;37(5):411â6. doi: 10.3109/0142159X.2014.993371</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/0142159X.2014.993371</ArticleId><ArticleId IdType="pubmed">25523012</ArticleId></ArticleIdList></Reference><Reference><Citation>Pershad Y, Hangge PT, Albadawi H, Oklu R. Social Medicine: Twitter in Healthcare. J Clin Med. 2018;7(6). doi: 10.3390/jcm7060121</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm7060121</ArticleId><ArticleId IdType="pmc">PMC6025547</ArticleId><ArticleId IdType="pubmed">29843360</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MA, Majhail NS, Wood WA, Perales MA, Chaboissier M. Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider. Curr Hematol Malig Rep. 2015;10(4):405â12. doi: 10.1007/s11899-015-0286-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11899-015-0286-x</ArticleId><ArticleId IdType="pmc">PMC4679678</ArticleId><ArticleId IdType="pubmed">26449718</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett CL, Gundabolu K, Kwak LW, Djulbegovic B, Champigneulle O, Josephson B, et al.. Using Twitter for the identification of COVID-19 vaccine-associated haematological adverse events. Lancet Haematol. 2022;9(1):e12âe3. doi: 10.1016/S2352-3026(21)00378-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(21)00378-1</ArticleId><ArticleId IdType="pmc">PMC8714180</ArticleId><ArticleId IdType="pubmed">34971576</ArticleId></ArticleIdList></Reference><Reference><Citation>Worldwide visits to Google.com from November 2022 to April 2023 (in billions) [Internet]. SimilarWeb. 2023 [cited October 13, 2023]. https://www.statista.com/statistics/268252/web-visitor-traffic-to-googlecom/.</Citation></Reference><Reference><Citation>Facebook Users, Stats, Data &amp; Trends [Internet]. Datareportal.com. 2023 [cited October 13, 2023]. https://datareportal.com/essential-facebook-stats.</Citation></Reference><Reference><Citation>Twitter Users, Stats, Data &amp; Trends [Internet]. Datareportal.com. 2023 [cited October 13, 2023]. https://datareportal.com/essential-twitter-stats.</Citation></Reference><Reference><Citation>Instagram Users, Stats, Data &amp; Trends [Internet]. Datareportal.com. 2023 [cited October 13, 2023]. https://datareportal.com/essential-instagram-stats.</Citation></Reference><Reference><Citation>Traffic Analytics: reddit.com [Internet]. Semrush.com. 2023 [cited Oct 13, 2023]. https://www.semrush.com/analytics/traffic/overview/?searchType=domain&amp;q=reddit.com.</Citation></Reference><Reference><Citation>Charness M, Gupta, Stack J et al. Rapid relapse of symptomatic Omnicron SARS CoV2 infection following early suppression with nirmatrelvir-ritonavir. (Version 1). ResearchSquare. April 26, 2022.</Citation></Reference><Reference><Citation>Charness M, Gupta K, Stack J et al. Rapid relapse of symptomatic Omnicron SARS CoV2 infection following early suppression with nirmatrelvir-ritonavir. (Version 2). ResearchSquare May 13, 2022.</Citation></Reference><Reference><Citation>Epling BP, Rocco JM, Boswell KL et al.. COVID-19 redux: clinicial, virologic, and immunologic evaluation after nirmatrelvir-ritonavir. medRxiv. June 17, 2022.</Citation></Reference><Reference><Citation>Boucau J, Uddin R, Marino C et al.. Virologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for COVID 19. medRxiv. May 26, 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384370</ArticleId><ArticleId IdType="pubmed">35737946</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulson JM, Adam A, Gray LA, Evans A. COVID-19 âReboundâ associated with nirmatrelvir-ritonavir. medRxiv. Research Square. May 22, 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>